학술논문
Panuveitis induced by brentuximab vedotin: a possible novel adverse event of an antibody-drug conjugate.
Document Type
Letter
Author
Source
Subject
*ANTIBODY-drug conjugates
*IRIDOCYCLITIS
*EYE pain
*ANAPLASTIC large-cell lymphoma
*
*
*
Language
ISSN
1042-8194
Abstract
To our knowledge, this is the first case report of panuveitis associated with BV described in the literature and the second report of uveitis during BV therapy [[3]]. Brentuximab vedotin (BV) is an antibody-drug conjugate composed of an anti-CD30 monoclonal antibody conjugated through a linker to the microtubule disturbing agent monomethyl auristatin E (MMAE). The improvement of the ocular symptoms following the BV discontinuation in the absence of other etiologies that could explain the panuveitis makes BV a likely culprit. [Extracted from the article]